1
|
Kidd DP. Neurological involvement by Behçet's syndrome: clinical features, diagnosis, treatment and outcome. Pract Neurol 2023; 23:386-400. [PMID: 37775123 DOI: 10.1136/pn-2023-003875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/11/2023] [Indexed: 10/01/2023]
Abstract
Neurological involvement in Behçet's syndrome arises predominately through an inflammatory meningoencephalitis characterised by perivenular inflammation due to activation of Th-17 immunological pathways. The brainstem is involved in 50% of cases, the diencephalon and other areas of the brain in 30%, and the spinal cord in 10%. Movement disorders and epilepsy may occur. Psychiatric syndromes may arise with brain and brainstem involvement, and cognitive disorders relate to the brain disease, to circulating inflammatory factors, and to fatigue and despondency. Eighty per cent of cases begin with a relapsing disease course, of whom 70% have only one attack, and 30% have a progressive disease course either from onset or following an initially relapsing course. Venous thrombosis leading to intracranial hypertension and cerebral venous infarction is less common and caused by inflammation in affected veins and a circulating prothrombotic state. Arterial involvement is rare and relates to an arteritis affecting large-sized and medium-sized vessels within the brain leading to infarction, subarachnoid and parenchymal haemorrhage, aneurysm formation and arterial dissection. There is a newly recognised disorder of cerebral cortical hypoperfusion. Cranial neuropathy, peripheral neuropathy and myositis are rare. There has been significant progress in understanding the pathophysiology and treatment of the systemic disease, leading to improved outcomes, but there has been no randomised trial of treatment in the neurological disorder.
Collapse
|
2
|
Piven VD, Krasnov VS, Lashok PA, Neofidoff NA, Bubnova EV, Totolyan NA. Behcet's disease with neurologic manifestations. Zh Nevrol Psikhiatr Im S S Korsakova 2019; 119:67-73. [DOI: 10.17116/jnevro201911910167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
3
|
Abstract
Behçet's disease (BD) is a chronic relapsing and remitting vasculitis of unknown aetiology. It has the capacity to affect almost all organ systems because of its potential to involve both arteries and veins of all sizes, resulting in significant organ-threatening morbidity and mortality. Traditionally known as the 'silk road' disease, it has a worldwide occurrence. The aetiopathological mechanisms of disease development in BD remain poorly understood, but genome wide studies show human leukocyte antigen and non-human leukocyte antigen associations. Environmental influences and genetic factors may have a role in the aetiopathogenetic mechanisms that lead to development of the disease, indicating the autoimmune and auto-inflammatory nature of BD. The evidence base for treatment is limited but new knowledge is emerging and current treatment options range from symptomatic treatment, through to non-biological and biological immunosuppressive drugs, to cover the spectrum of clinical manifestations.
Collapse
Affiliation(s)
- Jagdish R Nair
- National Behcet's Syndrome Centre of Excellence, Aintree University Hospital, Liverpool, UK
| | - Robert J Moots
- University of Liverpool and director, National Behcet's Syndrome Centre of Excellence, Aintree University Hospital, Liverpool, UK
| |
Collapse
|
4
|
Dutra LA, de Souza AWS, Grinberg-Dias G, Barsottini OGP, Appenzeller S. Central nervous system vasculitis in adults: An update. Autoimmun Rev 2017; 16:123-131. [PMID: 28087351 DOI: 10.1016/j.autrev.2016.12.001] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2016] [Accepted: 09/08/2016] [Indexed: 11/27/2022]
Abstract
Primary central nervous system vasculitis (PCNSV) is a challenging diagnosis due to broad clinical manifestations and variable specificity and sensitivity of laboratory and imaging diagnostic tools. Differential diagnosis includes reversible cerebral vasoconstriction syndrome (RCVS), secondary vasculitis of the CNS and other noninflammatory vasculopathies. Brain biopsy is essential for definitive diagnosis and to exclude mimickers. Recent data show that data large-vessel PCNSV present worse prognosis when compared to small-vessel PCNSV. Herein we review diagnosis and management of PCNSV, secondary vasculitis of CNS and RCVS.
Collapse
Affiliation(s)
- Lívia Almeida Dutra
- General Neurology Division, Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil
| | | | | | | | - Simone Appenzeller
- Rheumatology Division, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.
| |
Collapse
|
5
|
Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S, Hamuryudan V, Siva A, Kantarci OH. Infliximab is a plausible alternative for neurologic complications of Behçet disease. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2016; 3:e258. [PMID: 27458602 PMCID: PMC4950829 DOI: 10.1212/nxi.0000000000000258] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Accepted: 05/18/2016] [Indexed: 11/15/2022]
Abstract
Objective: We evaluated the effectiveness of infliximab in patients with neuro-Behçet syndrome for whom other immunosuppressive medications had failed. Methods: Patients whose common immunosuppressive medications fail in recurrent neuro-Behçet syndrome need an alternative. We report our experience with the tumor necrosis factor α blocker infliximab for long-term treatment of neuro-Behçet syndrome. We recruited patients within a multidisciplinary referral practice of Behçet disease and prospectively followed everyone with a neurologic symptom(s). Patients (n = 16) with ≥2 neurologic bouts (excluding purely progressive disease) while on another immunosuppressive treatment were switched to and successfully sustained on infliximab (5 mg/kg in weeks 0, 2, and 6, then once every 8 weeks; minimum follow-up duration ≥12 months). Infliximab was stopped within 2 months after initiation in one patient because of pulmonary and CNS tuberculosis. Results: Patients had stepwise worsening due to relapses in the Expanded Disability Status Scale modified for neuro-Behçet syndrome before switching to infliximab (median score of 5.0, range 2.0–7.0; median neuro-Behçet syndrome duration 29.1 months, range 5.0–180.7). Median duration of preinfliximab immunosuppressive medication use was 20.0 months (range 3.0–180.7). In all 15 patients, during infliximab treatment (median score 4.0, range 2.0–7.0; median duration 39.0 months, range 16.0–104.9 months), neurologic relapses were completely aborted and there was no further disability accumulation. Conclusion: We observed a significant beneficial effect of infliximab in neuro-Behçet syndrome. Classification of evidence: This study provides Class IV evidence that for patients with neuro-Behçet syndrome whose other immunosuppressive medications failed, infliximab prevents further relapses and stabilizes disability.
Collapse
Affiliation(s)
- Burcu Zeydan
- Departments of Neurology (B.Z., U.U., S.S., O.N.D., A.S.) and Rheumatology (E.S., S.U., V.H.), Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; and Department of Neurology (B.Z., O.H.K.), Mayo Clinic College of Medicine, Rochester, MN
| | - Ugur Uygunoglu
- Departments of Neurology (B.Z., U.U., S.S., O.N.D., A.S.) and Rheumatology (E.S., S.U., V.H.), Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; and Department of Neurology (B.Z., O.H.K.), Mayo Clinic College of Medicine, Rochester, MN
| | - Sabahattin Saip
- Departments of Neurology (B.Z., U.U., S.S., O.N.D., A.S.) and Rheumatology (E.S., S.U., V.H.), Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; and Department of Neurology (B.Z., O.H.K.), Mayo Clinic College of Medicine, Rochester, MN
| | - Onat N Demirci
- Departments of Neurology (B.Z., U.U., S.S., O.N.D., A.S.) and Rheumatology (E.S., S.U., V.H.), Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; and Department of Neurology (B.Z., O.H.K.), Mayo Clinic College of Medicine, Rochester, MN
| | - Emire Seyahi
- Departments of Neurology (B.Z., U.U., S.S., O.N.D., A.S.) and Rheumatology (E.S., S.U., V.H.), Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; and Department of Neurology (B.Z., O.H.K.), Mayo Clinic College of Medicine, Rochester, MN
| | - Serdal Ugurlu
- Departments of Neurology (B.Z., U.U., S.S., O.N.D., A.S.) and Rheumatology (E.S., S.U., V.H.), Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; and Department of Neurology (B.Z., O.H.K.), Mayo Clinic College of Medicine, Rochester, MN
| | - Vedat Hamuryudan
- Departments of Neurology (B.Z., U.U., S.S., O.N.D., A.S.) and Rheumatology (E.S., S.U., V.H.), Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; and Department of Neurology (B.Z., O.H.K.), Mayo Clinic College of Medicine, Rochester, MN
| | - Aksel Siva
- Departments of Neurology (B.Z., U.U., S.S., O.N.D., A.S.) and Rheumatology (E.S., S.U., V.H.), Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; and Department of Neurology (B.Z., O.H.K.), Mayo Clinic College of Medicine, Rochester, MN
| | - Orhun H Kantarci
- Departments of Neurology (B.Z., U.U., S.S., O.N.D., A.S.) and Rheumatology (E.S., S.U., V.H.), Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; and Department of Neurology (B.Z., O.H.K.), Mayo Clinic College of Medicine, Rochester, MN
| |
Collapse
|
6
|
Ovcharov PS, Lisitsyna TA, Vel'tishchev DY, Tardov MV, Burenchev DV, Alekberova ZS, Nasonov EL. [Neurological and psychiatric disorders in Behҫet's disease]. Zh Nevrol Psikhiatr Im S S Korsakova 2016. [PMID: 28635794 DOI: 10.17116/jnevro20161166176-86] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The data of the literature on epidemiology, clinical manifestations, diagnosis and treatment of Behcet's disease are presented. Particular attention is paid to international recommendations (2014) on the classification, diagnostic criteria and treatment of neurological symptoms of Behҫet disease.
Collapse
Affiliation(s)
- P S Ovcharov
- Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - T A Lisitsyna
- Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - D Yu Vel'tishchev
- Federal Medical Research Center of Psychiatry and Narcology Ministry of Health of Russia, Moscow, Russia
| | - M V Tardov
- Sverzhevsky Research Centre of Otorhinolaryngology, Moscow, Russia
| | - D V Burenchev
- City polyclinic #12, Department of health of Moscow, Moscow, Russia
| | - Z S Alekberova
- Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - E L Nasonov
- Nasonova Research Institute of Rheumatology, Moscow, Russia
| |
Collapse
|
7
|
Nair JR, Moots RJ. Behçet's disease: Review of management. INDIAN JOURNAL OF RHEUMATOLOGY 2015. [DOI: 10.1016/j.injr.2015.09.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
8
|
Longitudinal Myelitis of a Neuro-Behçet Patient. Arch Rheumatol 2015; 31:91-93. [PMID: 29900982 DOI: 10.5606/archrheumatol.2016.5441] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Accepted: 10/06/2015] [Indexed: 11/21/2022] Open
Abstract
Behçet's disease is a chronic, relapsing inflammatory disorder of unknown etiology. Neuro-Behçet's disease (NBD) occurs in approximately 5 to 49% of patients with Behçet's disease. Spinal cord involvement is very rare in NBD. In this article, we report a 22-year-old male patient of NBD with longitudinal myelitis involving the entire spinal cord. Patient was admitted with one-week of headache, vomiting, and urinary incontinence. Before admission, he felt motor weakness for two years and had noticed recurrent genital and oral ulcers with a frequency of more than three episodes per year for five years. T2-weighted spinal magnetic resonance images showed hyperintensities within the entire spinal cord. He was diagnosed as NBD with longitudinal myelitis. Intravenous methylprednisolone (120 mg/day) was administered for three days, followed by an oral administration of prednisolone (45 mg/day). In conjunction with the steroid therapy, intravenous cyclophosphamide (0.4 g/week) was administered twice. Rapid improvements were detected after receiving treatments for half a month. NBD associated longitudinal myelitis is really rare. This case provided important implications for the diagnosis and treatment of longitudinal myelitis in NBD patients.
Collapse
|
9
|
Abstract
Cogan and Behcet syndromes are considered large vessel vasculitides. Both are rare diseases, with varied clinical manifestations affecting multiple organ systems. Although both have hallmark symptoms (ocular and vestibuloauditory inflammation in Cogan syndrome and aphthous ulcers in Behcet syndrome), neither has confirmatory diagnostic testing. Delayed diagnosis can result in poor outcomes. In both syndromes, large vessel arterial inflammation may result in severe morbidity and mortality. Treatment strategies in both syndromes vary based on organ system involvement and severity of manifestations. In this article, the epidemiology, proposed pathogenesis, manifestations, and the most current treatment paradigms for these syndromes are reviewed.
Collapse
|
10
|
Rokutanda R, Kishimoto M, Okada M. Update on the diagnosis and management of Behçet's disease. Open Access Rheumatol 2014; 7:1-8. [PMID: 27790039 PMCID: PMC5045120 DOI: 10.2147/oarrr.s46644] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Behçet’s disease is a multi-organ disorder that is more common in countries around the Silk Road, and manifests as mucosal ulcers and skin lesions, and with ocular involvement. As a systemic disease, it can also involve gastrointestinal organs and the central nervous or cardiovascular systems. Although the etiology of Behçet’s disease is not clearly identified, the pathogenesis of the disease is most commonly hypothesized as a profound inflammatory response triggered by an infectious agent in a genetically susceptible host. As there are no single specific manifestations or specific diagnostic tests, various diagnostic criteria have been proposed around the world, and, among them, the International Study Group criteria have been most commonly used. As the clinical expression of Behçet’s disease is heterogeneous, the treatment should be individualized based on involved organs, severity of the disease, and patient’s background. The choice of therapeutic agents is limited by lack of clinical trials and is based largely on case reports, case series, and several open-label clinical trials. Corticosteroids, colchicine, and traditional immunosuppressive agents, including azathioprine and cyclosporine, have been used for the treatment of Behçet’s disease. Recently, tumor necrosis factor (TNF) inhibitors have become available for several rheumatic diseases, and considerable published data suggest that TNF inhibitors represent an important therapeutic advance for patients with severe and resistant disease, as well as for those with contraindications or intolerance to these treatments.
Collapse
Affiliation(s)
- Ryo Rokutanda
- Immuno-Rheumatology Center, St Luke's International Hospital, Tokyo, Japan
| | | | - Masato Okada
- Immuno-Rheumatology Center, St Luke's International Hospital, Tokyo, Japan
| |
Collapse
|
11
|
Nava F, Ghilotti F, Maggi L, Hatemi G, Del Bianco A, Merlo C, Filippini G, Tramacere I. Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behçet's Syndrome. Cochrane Database Syst Rev 2014; 2014:CD010729. [PMID: 25521793 PMCID: PMC10594584 DOI: 10.1002/14651858.cd010729.pub2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Neuro-Behçet Syndrome (NBS) is a severe chronic inflammatory vascular disease involving the Central Nervous System (CNS), and it is an invalidating condition with disability and a huge impact on quality of life. Recommendations on treatments for NBS include the use of disease-modifying therapies in general, although they are not supported by a systematic review of the evidence. OBJECTIVES To assess the benefit and harms of available treatments for NBS, including biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha. SEARCH METHODS We searched the following databases up to 30 September 2014: Trials Specialised Register of The Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group, CENTRAL, MEDLINE, EMBASE, CINAHL, LILACS, ORPHANET, Clinicaltrials.gov and World Health Organization (WHO) International Clinical Trials Registry Portal. SELECTION CRITERIA Randomised controlled trials (RCTs), controlled clinical trials (CCTs), prospective and retrospective controlled cohort studies were eligible to assess the benefit. Patients over 13 years of age with a diagnosis of NBS. For assessment of harms, open-label extension (OLE), case-control studies, population-based registries, case-series and case-reports were additionally planned to be evaluated. DATA COLLECTION AND ANALYSIS Selection of studies, data extraction and assessment of risk of bias were planned to be carried out independently by two review authors. Standard methodological procedures expected by The Cochrane Collaboration were followed. We planned to perform standard pair-wise meta-analyses for RCTs, and meta-analyses based on the adjusted estimates using the inverse-variance weighted average method for non-randomised studies (NRSs). We planned to present the main results of the review in a 'Summary of Findings' table using the GRADE approach. MAIN RESULTS No RCTs, CCTs or controlled cohort studies on the benefit of the treatments for NBS met the inclusion criteria of the review. Only one potentially eligible study was identified, but it did not report sufficient details on the patient characteristics. The author of this study did not provide additional data on request, and therefore it was excluded. Hence, no studies were included in the present review. Since no studies were included in the assessment of benefit, no further search was performed in order to collect data on harms. AUTHORS' CONCLUSIONS There is no evidence to support or refute the benefit of biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for the treatment of patients with NBS. Thus, well-designed multicentre RCTs are needed in order to inform and guide clinical practice.
Collapse
Affiliation(s)
- Francesca Nava
- University of Milano‐BicoccaFaculty of Statistical Sciencevia Bicocca degli Arcimboldi 8MilanItaly20126
| | - Francesca Ghilotti
- University of Milano‐BicoccaFaculty of Statistical Sciencevia Bicocca degli Arcimboldi 8MilanItaly20126
| | - Lorenzo Maggi
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaNeurology IV‐ Neuro‐Immunology and Neuromuscular DiseasesVia Celoria, 11MilanoItaly20133
| | - Gulen Hatemi
- Istanbul University, Cerrahpasa Medical SchoolDepartment of Internal Medicine, Division of RheumatologyCerrahpasa Tip Fakultesi, AksarayIstanbulTurkey34365
| | | | - Chiara Merlo
- Fondazione MarchiOspedale Di Circolo Del PonteVia Del Ponte, 19VareseVareseItaly21040
| | - Graziella Filippini
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaScientific Directionvia Celoria, 11MilanoItaly20133
| | - Irene Tramacere
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaNeuroepidemiology UnitVia Giovanni Celoria, 11MilanoItaly20133
| | | |
Collapse
|
12
|
Abstract
PURPOSE OF REVIEW There is agreement that the management of Behçet's syndrome has recently improved, especially with the wider use of biologics. The aim of this review is to summarize the current management strategies in Behçet's syndrome. RECENT FINDINGS There is growing experience with tumor necrosis factor-alpha antagonists in the management of eye gastrointestinal and nervous disease in Behçet's syndrome. Interferon-alpha at lower doses may increase its tolerability. Other biologics such as interleukin 1-blocking agents and tocilizumab were used in a small number of patients and also seem to be effective. SUMMARY Although experiences with biologics have expanded and looks promising, this is mostly observational or retrospective. There still is a lack of controlled trials with these agents, especially in patients with major organ involvement.
Collapse
|
13
|
Ozguler Y, Yazici H. Behçet's syndrome: New insights into pathogenesis and management. INDIAN JOURNAL OF RHEUMATOLOGY 2014. [DOI: 10.1016/j.injr.2014.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
14
|
Ohtsuka T. Entero-Behçet's disease coexisting with long-term epilepsy and schizophrenia-like symptoms. J Dermatol 2014; 41:424-6. [PMID: 24750420 DOI: 10.1111/1346-8138.12470] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2013] [Accepted: 02/18/2014] [Indexed: 11/28/2022]
Abstract
Entero-Behçet's disease coexisting with long-term epilepsy and schizophrenia-like symptoms is presented. A 43-year-old woman presented with repeatedly occurring aphthous stomatitis for several years. She had been treated for absence seizures, epilepsy and schizophrenia since she was 9 years old. She presented with multiple aphthous stomatitis on her gingiva, erythema nodosum-like symptoms on the right lateral aspect of her leg and genital ulcers on her perianal area. She also showed polyarthritis. Laboratory examinations revealed elevated C-reactive protein, elevated neutrophil counts, decreased serum Fe and elevated serum Cu. Histological examination showed perivascular neutrophil and mononuclear cell infiltrates and eosinophilic change of the vessel wall in the lobules of subcutaneous fat tissue. Six weeks after the oral prednisolone therapy, she showed resolution of aphthous stomatitis, folliculitis-like eruption and genital ulcer. She experienced severe abdominal pain after the start of treatment of Behçet's disease. Plain computed tomography revealed edematous change in the appendix, and ascending and transverse colon. These results led to the diagnosis of entero-Behçet's disease acute exaggeration. Treatment with infliximab (300 mg/once) was started. Eight weeks after the start of infliximab, her abdominal pain disappeared and C-reactive protein decreased, followed by the successful change to adalimumab infusion therapy.
Collapse
Affiliation(s)
- Tsutomu Ohtsuka
- Department of Dermatology, International University of Health and Welfare Hospital, Nasushiobara, Tochigi, Japan
| |
Collapse
|
15
|
Yoon DL, Kim YJ, Koo BS, Kim YG, Lee CK, Yoo B. Neuro-behçet's disease in South Korea: clinical characteristics and treatment response. Int J Rheum Dis 2014; 17:453-8. [PMID: 24506839 DOI: 10.1111/1756-185x.12265] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
AIM Neuro-behçet's disease (NBD) is a rare complication of Behçet's disease (BD) but is still important due to its morbidity and mortality. In this study, we sought to identify the characteristics of NBD by examining the clinical characteristics, and whether there were differences in the clinical characteristics or the treatment between relapsed and non-relapsed groups. METHODS We retrospectively reviewed the medical history of all patients diagnosed with BD at the Asan Medical Center in South Korea from January 1996 to May 2012. NBD was defined as neurological symptoms and compatible abnormalities identified by magnetic resononance imaging. RESULTS Among 624 BD patients, 22 were diagnosed with NBD. The common initial neurological symptoms were headache, gait disturbance and dysarthria. The common involved sites were the diencephalon, including internal capsule, the thalamus and basal ganglia, followed by the brainstem. An increased signal intensity on T2-weighted images was the most common finding. All patients had an improved disease state after steroid treatment, regardless of combined treatment with cyclophosphamide. However, eight patients experienced a disease recurrence at 7.3 ± 5.1 months after treatment. There were no significant differences in treatment patterns between the relapsed group and the non-relapsed group. CONCLUSIONS NBD may present with various neurologic manifestations with multifocal diencephalon and brainstem involvement. Most NBD patients had a good clinical outcome after steroid treatment, with or without a cytotoxic agent, but showed a pattern of relapse-remission. Therefore, careful long-term follow-up is needed in most cases of NBD.
Collapse
Affiliation(s)
- Da-Lim Yoon
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
| | | | | | | | | | | |
Collapse
|
16
|
Li J, Fernando S, Herkes G. Use of infliximab and other biologics in Behçet disease. Intern Med J 2014; 44:96-100. [DOI: 10.1111/imj.12297] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Accepted: 07/14/2013] [Indexed: 11/29/2022]
Affiliation(s)
- J. Li
- Department of Clinical Immunology and Allergy; Royal North Shore Hospital; Sydney New South Wales Australia
| | - S. Fernando
- Department of Clinical Immunology and Allergy; Royal North Shore Hospital; Sydney New South Wales Australia
| | - G. Herkes
- Department of Neurology; Royal North Shore Hospital; Sydney New South Wales Australia
| |
Collapse
|
17
|
Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations. J Neurol 2013; 261:1662-76. [PMID: 24366648 PMCID: PMC4155170 DOI: 10.1007/s00415-013-7209-3] [Citation(s) in RCA: 182] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2013] [Accepted: 12/04/2013] [Indexed: 11/16/2022]
Abstract
Neuro-Behçet’s disease (NBD) is one of the more serious manifestations of Behçet’s disease (BD), which is a relapsing inflammatory multisystem disease with an interesting epidemiology. Though NBD is relatively uncommon, being potentially treatable, neurologists need to consider it in the differential diagnosis of inflammatory, infective, or demyelinating CNS disorders. Evidence-based information on key issues of NBD diagnosis and management is scarce, and planning for such studies is challenging. We therefore initiated this project to develop expert consensus recommendations that might be helpful to neurologists and other clinicians, created through an extensive literature review and wide consultations with an international advisory panel, followed by a Delphi exercise. We agreed on consensus criteria for the diagnosis of NBD with two levels of certainty in addition to recommendations on when to consider NBD in a neurological patient, and on the use of various paraclinical tests. The management recommendations included treatment of the parenchymal NBD and cerebral venous thrombosis, the use of disease modifying therapies, prognostic factors, outcome measures, and headache in BD. Future studies are needed to validate the proposed criteria and provide evidence-based treatments.
Collapse
|
18
|
Kanemaru H, Makino T, Jinnin M, Yonemitsu A, Makino K, Ihn H. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years. J Dermatol 2013; 40:632-4. [PMID: 23724912 DOI: 10.1111/1346-8138.12203] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2013] [Accepted: 04/22/2013] [Indexed: 10/26/2022]
Abstract
Behçet's disease is a systemic inflammatory disorder with chronic remissions and relapses. Involvement of the central nervous system, called neuro-Behçet's disease (NBD), is a serious complication. Although corticosteroids and immunosuppressive agents are used, there is no definite standard of treatment with long term-effects for NBD. Here, we report a female case with NBD successfully treated by infliximab and corticosteroids for 2 years. Our report suggests treatment with infliximab may be effective for long-term remission of NBD.
Collapse
Affiliation(s)
- Hisashi Kanemaru
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
| | | | | | | | | | | |
Collapse
|
19
|
Abstract
Behçet's syndrome (BS) shows a peculiar distribution, with a much higher prevalence in countries along the ancient Silk Road compared with rest of the world. BS also seems to follow a more severe course in ethnic groups with higher prevalence. Diagnosis depends on clinical findings. Criteria sets may not help in patients with less frequent types of involvement. Management strategies should be modified according to the age and sex of the patient and the organs involved. Being a serious health problem in endemic areas, BS also attracts global attention as a model to study inflammatory diseases of unknown cause.
Collapse
Affiliation(s)
- Gulen Hatemi
- Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Cerrahpasa, Istanbul 34089, Turkey
| | | | | |
Collapse
|